Session » Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events
-
Abstract Number: 2460
Predictive Factors of Good Response to Conventional Dmards in Patients with Early Seronegative Rheumatoid Arthritis: Data from the Espoir Cohort
-
Abstract Number: 2461
Identifying Flare in Rheumatoid Arthritis: What Is the Threshold?
-
Abstract Number: 2463
Association Between High Sodium Intake and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
-
Abstract Number: 2464
Comparison of Disease Activity Score (DAS) 28-CRP to DAS28-ESR in Patients with Active Rheumatoid Arthritis
-
Abstract Number: 2465
Discordance Between Tender and Swollen Joint Count and Patient’s and Evaluator’s Global Assessment May Reduce Likelihood of Remission in Rheumatoid Arthritis
-
Abstract Number: 2466
Remission According to RAPID3 (routine assessment of patient index data 3) in Patients with Rheumatoid Arthritis: A Cross-Sectional 3 Center Study from Routine Care
-
Abstract Number: 2467
Validation of the FLARE Questionnaire for the Detection of a Disease Flare in Rheumatoid Arthritis
-
Abstract Number: 2468
Assessment of the American-English Version of the French FLARE in Rheumatoid Arthritis
-
Abstract Number: 2469
How Rheumatoid Arthritis Patients and Rheumatologists Communicate during Clinic Visits When a New DMARD Is Prescribed
-
Abstract Number: 2470
Treat to Target: Theoretical Agreement Vs Daily Applicability
-
Abstract Number: 2472
Early DAS28 Drop Is a Predictor for Clinical Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis: An Observational Study of a Real Life Inception Cohort
-
Abstract Number: 2473
Concordance Between the Patient, Nurse and Physician Assessment of Clinical Outcomes in a Cohort of Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
-
Abstract Number: 2474
Patients’ Experiences of Using a Smartphone App for Remote Monitoring of Rheumatoid Arthritis, Integrated into the Electronic Medical Record, and Its Impact on Consultations
-
Abstract Number: 2475
Identifying Key Variables for Inclusion in a Smartphone App to Support Clinical Care and Research in Patients with Rheumatoid Arthritis
-
Abstract Number: 2476
Performance of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Appears to be Better Than Gold Standard Disease Assessment Score (DAS-28 CRP)
-
Abstract Number: 2477
Short Term Clinical Response to Initial Treatment with High Versus Low Dose Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients
-
Abstract Number: 2478
Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort
-
Abstract Number: 2479
Work Productivity in Early Rheumatoid Arthritis Patients Treated before and after Implementation of a Treat-to-Target Strategy
-
Abstract Number: 2480
Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis
-
Abstract Number: 2481
Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis
-
Abstract Number: 2482
Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate
-
Abstract Number: 2483
Results of a Pilot Study of a Tailored Symptom Assessment Tool to Enhance Patient-Centered Care in Rheumatoid Arthritis: Choice RA
-
Abstract Number: 2484
Real World Treat to Target Strategy in Rheumatoid Arthritis: Radiograph and MRI Outcomes in Three Cohorts with 18 Month Follow up
-
Abstract Number: 2485
Correlates of Successful Flare Management: The Role of Clinician-Driven Treatment, Home-Based Strategies, and Medication Change
-
Abstract Number: 2486
Effect of a Dynamic Exercise Program in Combination with a Mediterranean Diet in Strength, Joint Mobility and Disease Activity in Women with Rheumatoid Arthritis
-
Abstract Number: 2487
In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare
-
Abstract Number: 2488
A Randomised Controlled Trial Evaluating the Effect of Adalimumab upon Biomarkers of Cardiovascular Risk in ACPA-Positive Rheumatoid Arthritis
-
Abstract Number: 2490
Impact of Obesity Activity Indices and Therapeutic Dosage in Patients with Rheumatoid Arthritis in Dominican Republic
-
Abstract Number: 2491
Is It Possible to Predict Which Patients Treated with Biologic Agents for Rheumatic Diseases Will Develop Anti-Drug Antibodies ?
-
Abstract Number: 2492
Mode of Administration in Rheumatoid Arthritis Treatments: An Exploration of Patient Preference for an ‘Ideal Treatment’
-
Abstract Number: 2493
Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab
-
Abstract Number: 2494
The Effect of Body Mass on DAS28 Response in Patients with Rheumatoid Arthritis Treated with Abatacept
-
Abstract Number: 2495
The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
-
Abstract Number: 2496
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
-
Abstract Number: 2497
Associations Between Dietary Intake of Vitamin D, Omega-3 Fatty Acids, Folate and EULAR Response in Patients with Early Rheumatoid Arthritis
-
Abstract Number: 2498
Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis
-
Abstract Number: 2499
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
-
Abstract Number: 2500
Prevalence of Sustained Remission in Patients with Rheumatoid Arthritis in Sweden. Impact of Criteria Sets and Early Treatment, a Nationwide Register Study in Sweden
-
Abstract Number: 2501
Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort
-
Abstract Number: 2502
Tocilizumab Therapy Reduces Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms
-
Abstract Number: 2503
Making Room for RA Patient Symptoms into Treatment Decision: A Physician Perspective Study
-
Abstract Number: 2504
Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept
-
Abstract Number: 2505
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
-
Abstract Number: 2506
Seropositivity Predicts Bone Biomarker Change in an Inception Cohort of Rheumatoid Arthritis Patients Treated-to-Target with Combination Conventional DMARD Therapy
-
Abstract Number: 2507
Assessment of Liver Fibrosis Using Transient Elastography in Patients with Rheumatoid Arthritis Exposed to Long Term Methotrexate
-
Abstract Number: 2508
Significant Improvement of Rheumatoid Arthritis (RA) Outcome with Repeat Application of Disease Management (SSDM) Mobiles Tools: A Cohort Study of RA Patients in China
-
Abstract Number: 2509
Implementation of the Treat to Target Concept in Evaluation of Rheumatoid Arthritis Patients
-
Abstract Number: 2510
Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases
-
Abstract Number: 2511
Longitudinal Observation of Disease Activity and Treatment of Rheumatoid Arthritis Who Developed Methotrexate-Associated Lymphoproliferative Disorders
-
Abstract Number: 2512
Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden
-
Abstract Number: 2513
Maintained Remission in Rheumatoid Arthritis over 7 Years in «Real Life Conditions» : A Monocentric Observational Study
-
Abstract Number: 2516
Concomitant Use of Oral Vs. Subcutaneous Methotrexate at Biologic Initiation: A Comparison of Biologic Treatment Survival in a Rheumatoid Arthritis Cohort
-
Abstract Number: 2517
Long-Term Stability of the 5-Item Compliance Questionnaire Rheumatology As a Measure of Adherence in Patients with Rheumatoid Arthritis
-
Abstract Number: 2518
Intensive Treatment for Rheumatoid Arthritis Reduces Disease Activity over Time
-
Abstract Number: 2519
Predictors of Flare in Rheumatoid Arthritis Patients Treated Preventively with Rituximab: A Prospective Study Using Ultrasound and Patient Reported Outcomes
-
Abstract Number: 2520
Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab
-
Abstract Number: 2521
Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients
-
Abstract Number: 2522
Pharmacomicrobiomics of Methotrexate: Baseline Intestinal Microbiota Correlates with Therapeutic Response
-
Abstract Number: 2523
Reasons for Provider Non-Adherence to a Treat to Target Strategy in Rheumatoid Arthritis
-
Abstract Number: 2524
Achievement of Imaging Remission Among Patients with Rheumatoid Arthritis in Clinical Remission and Their Characteristics
-
Abstract Number: 2525
Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis
-
Abstract Number: 2526
TNF Blocker Concentrations or Detection of Antibodies Against Anti-TNF before a Tapering Process Are Not Predictive to Relapse
-
Abstract Number: 2527
Drug Retention of Biologics in Rheumatoid Arthritis Patients: The Role of Baseline Characteristics and Impact of Time-Varying Factors
-
Abstract Number: 2528
Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study
-
Abstract Number: 2529
Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
-
Abstract Number: 2530
Patient´s Motivations for Non-Persistence with Medication Impact How They Score Compliance
-
Abstract Number: 2531
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Functional and Clinical Outcomes Among Patients with Rheumatoid Arthritis: Passion Study
-
Abstract Number: 2532
Methotrexate Adherence in an Online Network of Patients with Rheumatoid Arthritis
-
Abstract Number: 2533
Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?
-
Abstract Number: 2534
Radiographic Remission in Patients with Seropositive RA at Ten Years after Diagnosis, Treated in a Real Life Setting
-
Abstract Number: 2535
Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
-
Abstract Number: 2536
The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis
-
Abstract Number: 2537
High Retention Rates and Clinical Efficacy of Tocilizumab As First-Line Biologic Treatment in Patients with Rheumatoid Arthritis
-
Abstract Number: 2538
Comparison of Intravenous Versus Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis in a Routine Clinical Care Setting: A Preliminary, Time to Response Analysis
-
Abstract Number: 2540
The Longitudinal Impact of Biologic Use on Disability within a RA Registry
-
Abstract Number: 2541
Glucocorticoid Use and Low Thoracic Bone Mineral Density Are Predictors for Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
-
Abstract Number: 2542
Reducing the Dosage of Glucocorticoid to Zero Might Decrease Risk of Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
-
Abstract Number: 2543
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
-
Abstract Number: 2544
Glucocorticoid Treatment for 12 Weeks in Early Rheumatoid Arthritis Is Related to an Increase in BMI
-
Abstract Number: 2545
Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis
-
Abstract Number: 2546
Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer
-
Abstract Number: 2547
Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis
-
Abstract Number: 2548
Single 1g Infusion Vs Double 1g Infusion of Rituximab in Rheumatoid Arthritis in a Large Teaching Hospital: Potential Clinical Benefits and Financial Savings
-
Abstract Number: 2549
Effect of Interleukin-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type 9 Serum Levels in Rheumatoid Arthritis Patients
-
Abstract Number: 2550
Long Persistence of Anti-Drug Antibodies in Adalimumab Treated RA Patients
-
Abstract Number: 2552
Predictive Value of Chest HRCT Patterns for Respiratory Adverse Event Among RA Patients Treated with Biological Therapy: Long-Term Results from an Observational Study
-
Abstract Number: 2553
Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database